好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Joint Commission (TJC)/Disease-Specific Care (DSC) Certification Programs for Parkinson's Disease (PD)/Multiple Sclerosis (MS)/Amyotrophic Lateral Sclerosis (ALS) - A Structured Mechanism Developed for Guideline-Directed Performance Measure Implementation, Audit and Compliance Assessment Allowing Evolution from Process-Based to Patient-Outcome-Based Improvement in Patient Care at Carolinas Medical Center
Movement Disorders
P04 - (-)
189
BACKGROUND: TJC/DSC Certification is a clinic-based process that assesses implementation of performance measures based on known guidelines (www.jointcommission.org/certification/diseasespecific_care.aspx). The reiterative process was introduced to improve the quality of patient care by reducing variation in clinical processes reducing the risk of error, develop a framework for program structure and management using effective data-driven performance improvement, provide an objective assessment of clinical excellence, and potentially meet necessary regulatory requirements. The process is amenable to existing guidelines and performance measures recently developed by the 好色先生(AAN).
DESIGN/METHODS: Standardized performance measures defined by AAN/National Patient Safety goals:(1) Cognitive [Mini-Mental Status Examination[MMSE](PD/ALS), Digit-Span(MS)], (2) Depression[Patient Health Questionnaire[PHQ-2/PHQ-9](ALS), Geriatric Depression Scale(PD), Beck Depression Scale(MS)], (3)Falls Assessment (PD), (4)25-Foot-Walk(MS), (5)Communication with primary care physician(PCP) (PD/MS/ALS), (6)Respiratory Management Assessment(RMA) (ALS) were monitored at Carolinas Medical Center with monthly/quarterly audits of performance ascertained in 538 PD, 1574 MS and 311 ALS patients across 1754卤332(SD)PD, 3627卤592 MS, 1406卤384 ALS annual encounters over two years.
RESULTS: Monthly audits indicated high protocol compliance in (1)cognitive-screening[98.9卤11.7%], (2)depression-screening[98.4卤17.4%], (3)falls assessment [96.2卤19.2%], (4)25-Foot-Walk[98.8卤5.7%], (5)communications with PCP[85.5卤16.8%]assessments across the disease programs according to practice standards. (6)RMA identified functional vital capacity(FVC) measurement as universal(100.0卤0.0%)and the measure was adjusted to assess the proportion of patients with FVC<60%predicted offered respiratory support.
CONCLUSIONS: TJC/DSC certification is a clinic-based process for implementing performance measures to improve PD/MS/ALS clinic performance at Carolinas Medical Center. Deployment of performance measures was accomplished with compliance achieving benchmark targets providing an improved culture of guideline-based patient care with mechanisms in place to audit and continually verify adherence. The TJC/DSC certification process allows regular addition of new performance measures to achieve these ends.
Authors/Disclosures
Jill Conway, MD
PRESENTER 		No disclosure on file
Danielle Englert, MD Dr. Englert has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyowa Kirin. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for adamas. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for acadia.
Elena Bravver, MD No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Dimitri M. Kullmann No disclosure on file
No disclosure on file
Michael D. Kaufman, MD (Knoxville Neurology Clinic) No disclosure on file
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC) Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.
Sanjay S. Iyer, MD (Memory and Movement Charlotte) Dr. Iyer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TEVA. Dr. Iyer has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurocrine. Dr. Iyer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Adamas. Dr. Iyer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for USWM.